HRP20200649T1 - Novi derivat kinolina za upotrebu u liječenju i sprječavanju virusnih infekcija - Google Patents
Novi derivat kinolina za upotrebu u liječenju i sprječavanju virusnih infekcija Download PDFInfo
- Publication number
- HRP20200649T1 HRP20200649T1 HRP20200649TT HRP20200649T HRP20200649T1 HR P20200649 T1 HRP20200649 T1 HR P20200649T1 HR P20200649T T HRP20200649T T HR P20200649TT HR P20200649 T HRP20200649 T HR P20200649T HR P20200649 T1 HRP20200649 T1 HR P20200649T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- formula
- image
- compound
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003248 quinolines Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims 1
- 150000001661 cadmium Chemical class 0.000 claims 1
- 229910000011 cadmium carbonate Inorganic materials 0.000 claims 1
- GKDXQAKPHKQZSC-UHFFFAOYSA-L cadmium(2+);carbonate Chemical compound [Cd+2].[O-]C([O-])=O GKDXQAKPHKQZSC-UHFFFAOYSA-L 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- AHCNXVCAVUYIOU-UHFFFAOYSA-M lithium hydroperoxide Chemical compound [Li+].[O-]O AHCNXVCAVUYIOU-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (7)
1. Derivat kinolina s formulom (1)
[image]
ili jedna od njegovih farmaceutski prihvatljivih soli.
2. Derivat kinolina u skladu s patentnim zahtjevom 1, ili jedna od njegovih farmaceutski prihvatljivih soli, naznačen time da se upotrebljava kao lijek.
3. Kinolin s formulom (1) prema patentnom zahtjevu 1, li jedna od njegovih farmaceutski prihvatljivih soli, naznačen time da se upotrebljava za liječenje ili sprječavanje virusne ili retrovirusne infekcije, te naročito AIDS-a ili stanja povezanog s AIDS-om ili virusom humane imunodeficijencije (HIV).
4. Farmaceutski pripravak naznačen time što sadrži derivat kinolina u skladu s patentnim zahtjevom 1, jednu od njegovih farmaceutski prihvatljivih soli, te barem jednu farmaceutski prihvatljivu pomoćnu tvar.
5. Lijek naznačen time što sadrži derivat kinolina u skladu s patentnim zahtjevom 1, ili jednu od njegovih farmaceutski prihvatljivih soli.
6. Postupak za pripremu derivata kinolina prema patentnom zahtjevu 1, naznačen time što sadrži korak obrade spoja (4)
[image]
u otopini litijevog hidroperoksida, na primjer u otapalu kao što je tetrahidrofuran ili dioksin, kojem proizvoljno prethodi korak dobivanja spoja (4) koji se sastoji od reakcije spoja formule (2)
[image]
sa spojem formule (3):
[image]
u prisutnosti soli teškog metala kao što je kadmijeva sol, na primjer kadmijev karbonat, naročito u otapalu kao što je nitrometan, obično pri temperaturi refluksa otapala.
7. Spoj formule (4)
[image]
ili jedna od njegovih farmaceutski prihvatljivih soli.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305274.1A EP3059236A1 (en) | 2015-02-23 | 2015-02-23 | A new quinoline derivative for use in the treatment and prevention of viral infections |
EP16705515.1A EP3262037B1 (en) | 2015-02-23 | 2016-02-19 | A new quinoline derivative for use in the treatment and prevention of viral infections |
PCT/EP2016/053532 WO2016135052A1 (en) | 2015-02-23 | 2016-02-19 | A new quinoline derivative for use in the treatment and prevention of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200649T1 true HRP20200649T1 (hr) | 2020-10-16 |
Family
ID=52629497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200649TT HRP20200649T1 (hr) | 2015-02-23 | 2020-04-22 | Novi derivat kinolina za upotrebu u liječenju i sprječavanju virusnih infekcija |
Country Status (22)
Country | Link |
---|---|
US (1) | US10329317B2 (hr) |
EP (2) | EP3059236A1 (hr) |
JP (1) | JP6797126B2 (hr) |
KR (1) | KR102583506B1 (hr) |
CN (1) | CN107531681B (hr) |
AU (1) | AU2016223687B2 (hr) |
BR (1) | BR112017017500B1 (hr) |
CA (1) | CA2975577C (hr) |
CU (1) | CU24525B1 (hr) |
DK (1) | DK3262037T3 (hr) |
ES (1) | ES2785374T3 (hr) |
HR (1) | HRP20200649T1 (hr) |
HU (1) | HUE048577T2 (hr) |
LT (1) | LT3262037T (hr) |
MX (1) | MX2017010506A (hr) |
PL (1) | PL3262037T3 (hr) |
PT (1) | PT3262037T (hr) |
RS (1) | RS60369B1 (hr) |
RU (1) | RU2723013C2 (hr) |
SI (1) | SI3262037T1 (hr) |
WO (1) | WO2016135052A1 (hr) |
ZA (1) | ZA201705633B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
US20190034990A1 (en) * | 2017-07-26 | 2019-01-31 | International Business Machines Corporation | Information insight system for providers of products or services |
EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3881844A1 (en) * | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
CN115605205A (zh) * | 2020-03-20 | 2023-01-13 | Abivax公司(Fr) | 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途 |
EP3884946A1 (en) * | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
CN117222639A (zh) * | 2021-05-27 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
EP4201948A1 (en) | 2021-12-21 | 2023-06-28 | Abivax | Method of preparation of 1-(n-(quinolin-2-yl)-(phenylamino)-1-deoxy-beta-d-glucopyranuronic acid derivatives |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) * | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
WO2024109937A1 (zh) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种喹啉胺类化合物的可药用盐、晶型及其制备方法 |
WO2024109936A1 (zh) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种喹啉胺类化合物晶型及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
AU2010258214B2 (en) * | 2009-06-12 | 2015-08-20 | Abivax | Compounds useful for treating premature aging and in particular progeria |
EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
PL3016656T3 (pl) * | 2013-07-05 | 2022-02-21 | Abivax | Związki cykliczne użyteczne w leczeniu chorób wywoływanych przez retrowirusy |
EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
-
2015
- 2015-02-23 EP EP15305274.1A patent/EP3059236A1/en not_active Withdrawn
-
2016
- 2016-02-19 ES ES16705515T patent/ES2785374T3/es active Active
- 2016-02-19 CA CA2975577A patent/CA2975577C/en active Active
- 2016-02-19 RS RS20200447A patent/RS60369B1/sr unknown
- 2016-02-19 EP EP16705515.1A patent/EP3262037B1/en active Active
- 2016-02-19 SI SI201630722T patent/SI3262037T1/sl unknown
- 2016-02-19 MX MX2017010506A patent/MX2017010506A/es unknown
- 2016-02-19 HU HUE16705515A patent/HUE048577T2/hu unknown
- 2016-02-19 BR BR112017017500-2A patent/BR112017017500B1/pt active IP Right Grant
- 2016-02-19 KR KR1020177023445A patent/KR102583506B1/ko active IP Right Grant
- 2016-02-19 WO PCT/EP2016/053532 patent/WO2016135052A1/en active Application Filing
- 2016-02-19 CU CU2017000109A patent/CU24525B1/es unknown
- 2016-02-19 CN CN201680011519.7A patent/CN107531681B/zh active Active
- 2016-02-19 AU AU2016223687A patent/AU2016223687B2/en active Active
- 2016-02-19 DK DK16705515.1T patent/DK3262037T3/da active
- 2016-02-19 US US15/552,587 patent/US10329317B2/en active Active
- 2016-02-19 LT LTEP16705515.1T patent/LT3262037T/lt unknown
- 2016-02-19 PT PT167055151T patent/PT3262037T/pt unknown
- 2016-02-19 RU RU2017128643A patent/RU2723013C2/ru active
- 2016-02-19 PL PL16705515T patent/PL3262037T3/pl unknown
- 2016-02-19 JP JP2017543995A patent/JP6797126B2/ja active Active
-
2017
- 2017-08-18 ZA ZA2017/05633A patent/ZA201705633B/en unknown
-
2020
- 2020-04-22 HR HRP20200649TT patent/HRP20200649T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US10329317B2 (en) | 2019-06-25 |
PL3262037T3 (pl) | 2020-10-19 |
DK3262037T3 (da) | 2020-05-04 |
RU2017128643A (ru) | 2019-03-25 |
EP3262037B1 (en) | 2020-02-12 |
RS60369B1 (sr) | 2020-07-31 |
BR112017017500B1 (pt) | 2023-04-04 |
CA2975577A1 (en) | 2016-09-01 |
RU2017128643A3 (hr) | 2019-04-15 |
US20180030078A1 (en) | 2018-02-01 |
LT3262037T (lt) | 2020-07-10 |
PT3262037T (pt) | 2020-04-09 |
EP3262037A1 (en) | 2018-01-03 |
BR112017017500A2 (pt) | 2018-04-17 |
MX2017010506A (es) | 2017-11-13 |
RU2723013C2 (ru) | 2020-06-08 |
SI3262037T1 (sl) | 2020-09-30 |
CU24525B1 (es) | 2021-06-08 |
JP2018507215A (ja) | 2018-03-15 |
WO2016135052A1 (en) | 2016-09-01 |
JP6797126B2 (ja) | 2020-12-09 |
AU2016223687A1 (en) | 2017-08-31 |
HUE048577T2 (hu) | 2020-07-28 |
CN107531681B (zh) | 2020-11-24 |
ES2785374T3 (es) | 2020-10-06 |
KR102583506B1 (ko) | 2023-09-26 |
ZA201705633B (en) | 2018-12-19 |
KR20170129698A (ko) | 2017-11-27 |
CU20170109A7 (es) | 2018-02-08 |
CA2975577C (en) | 2020-04-07 |
CN107531681A (zh) | 2018-01-02 |
EP3059236A1 (en) | 2016-08-24 |
AU2016223687B2 (en) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200649T1 (hr) | Novi derivat kinolina za upotrebu u liječenju i sprječavanju virusnih infekcija | |
HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
EA201891876A1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
EP3954679A3 (en) | Amide compounds for the treatment of hiv infections | |
NZ631762A (en) | 5-membered heteroaryls and their use as antiviral agents | |
EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
PH12017501258B1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
EA201890200A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
EP3757105A3 (en) | Polycyclic pyridone derivative having integrase inhibitory activity | |
EA201590862A1 (ru) | Фармацевтические композиции | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2015015500A (es) | Composiciones de cenicriviroc y metodos para elaborarlas y usarlas. | |
HRP20201645T1 (hr) | Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent | |
WO2019244066A3 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
WO2012174312A3 (en) | Benzimidazole derivatives as antiviral agents | |
CO2018001359A2 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с | |
WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
WO2016195522A3 (en) | Antiviral composition | |
WO2015199418A3 (ko) | 신규한 헤테로고리 화합물 | |
WO2014124092A3 (en) | Lamivudine crystalline salts | |
BR112018000179A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. | |
WO2015154883A8 (en) | Neosoraphens |